VICP Registry Case Source Bundle
Canonical URL: https://vicp-registry.org/case/USCOURTS-cofc-1_16-vv-00169
Package ID: USCOURTS-cofc-1_16-vv-00169
Petitioner: Annette Eberhart
Filed: 2017-01-03
Decided: 2017-01-31
Vaccine: Tdap
Vaccination date: 2013-02-07
Condition: Guillain-Barré syndrome
Outcome: compensated
Award amount USD: 84464

AI-assisted case summary:
Annette Eberhart filed a petition on January 3, 2017, seeking compensation under the National Vaccine Injury Compensation Program. She alleged that she suffered from Guillain-Barré syndrome (GBS) as a result of receiving a Tetanus-diphtheria-acellular pertussis (Tdap) vaccine on February 7, 2013, and that she experienced residual effects for more than six months. The respondent denied that the Tdap vaccination caused her alleged GBS or any other injury. However, both parties agreed in a stipulation, filed on January 3, 2017, that the issues could be settled and that a decision should be entered awarding Petitioner compensation. Special Master Brian H. Corcoran reviewed the file and concluded that the stipulation was reasonable, adopting it as the decision. The stipulation awarded Annette Eberhart a lump sum of $84,464.00, representing compensation for all damages available under the Act. The public decision does not describe the onset of symptoms, specific medical tests, treatments, or expert witnesses. Petitioner was represented by Joseph T. McFadden of Rawls, McNelis & Mitchell, and Respondent was represented by Alexis B. Babcock of the U.S. Department of Justice.

Theory of causation field:
Petitioner Annette Eberhart alleged that she suffered from Guillain-Barré syndrome (GBS) as a result of receiving a Tetanus-diphtheria-acellular pertussis (Tdap) vaccine on February 7, 2013, and experienced residual effects for more than six months. Respondent denied causation. The parties reached a stipulation to settle the case, agreeing that a decision should be entered awarding Petitioner compensation. The stipulation was adopted by Special Master Brian H. Corcoran on January 31, 2017. The public decision does not specify the theory of causation, the mechanism of injury, or name any medical experts. The award was a lump sum of $84,464.00. Petitioner's counsel was Joseph T. McFadden, and Respondent's counsel was Alexis B. Babcock.

Public staged source text:

================================================================================
DOCUMENT 1: USCOURTS-cofc-1_16-vv-00169-0
Date issued/filed: 2017-01-31
Pages: 7
Docket text: PUBLIC DECISION (Originally filed: 01/03/2017) Regarding 18 DECISION: Stipulation. Signed by Special Master Brian H. Corcoran. (ed) Copy to parties.
--------------------------------------------------------------------------------
Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 1 of 7
In the United States Court of Federal Claims
OFFICE OF SPECIAL MASTERS
No. 16-169V
* * * * * * * * * * * * * * * * * * * * * * * * *
* Special Master Corcoran
ANNETTE EBERHART, *
*
Petitioner, * Filed: January 3, 2017
*
v. *
* Decision by Stipulation; Damages;
SECRETARY OF HEALTH * Tetanus-diphtheria-acellular pertussis
AND HUMAN SERVICES, * (“Tdap”) Vaccine; Guillain-Barré
* Syndrome (“GBS”).
Respondent. *
*
* * * * * * * * * * * * * * * * * * * * * * * * *
Joseph T. McFadden, Rawls, McNelis & Mitchell, Norfolk, VA, for Petitioner.
Alexis B. Babcock, U.S. Dep’t of Justice, Washington, DC, for Respondent.
DECISION AWARDING DAMAGES1
On February 4, 2016, Annette Eberhart filed a petition seeking compensation under the
National Vaccine Injury Compensation Program (“Vaccine Program”).2 Petitioner alleges that she
suffered from Guillain-Barré syndrome (“GBS”) as a result of her February 7, 2013, receipt of the
Tetanus-diphtheria-acellular pertussis (“Tdap”) vaccine. Moreover, Petitioner alleges that she
experienced residual effects of this injury for more than six months.
1 Because this decision contains a reasoned explanation for my actions in this case, I will post it on the United States
Court of Federal Claims website, in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012). As
provided by 42 U.S.C. § 300aa-12(d)(4)(B), however, the parties may object to the decision’s inclusion of certain
kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party has fourteen days within which
to request redaction “of any information furnished by that party: (1) that is a trade secret or commercial or financial
in substance and is privileged or confidential; or (2) that includes medical files or similar files, the disclosure of which
would constitute a clearly unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole decision will
be available to the public. Id.
2 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660,
100 Stat. 3758, codified as amended at 42 U.S.C. §§ 300aa-10 through 34 (2012) (“Vaccine Act” or “the Act”).
Individual section references hereafter will be to § 300aa of the Act (but will omit that statutory prefix).

Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 2 of 7
Respondent denies that Petitioner’s Tdap vaccination caused her alleged GBS, or any other
injury or condition. Nonetheless both parties, while maintaining their above-stated positions,
agreed in a stipulation (filed on January 3, 2017) that the issues before them could be settled, and
that a decision should be entered awarding Petitioner compensation.
I have reviewed the file, and based upon that review, I conclude that the parties’ stipulation
(as attached hereto) is reasonable. I therefore adopt it as my decision in awarding damages on the
terms set forth therein.
The stipulation awards:
 A lump sum of $84,464.00 in the form of a check payable to Petitioner.
Stipulation ¶ 8. This amount represents compensation for all damages that would be available
under Section 15(a) of the Act.
I approve a Vaccine Program award in the requested amount set forth above to be made to
Petitioner. In the absence of a motion for review filed pursuant to RCFC Appendix B, the clerk of
the Court is directed to enter judgment herewith.3
IT IS SO ORDERED.
/s/ Brian H. Corcoran
Brian H. Corcoran
Special Master
3 Pursuant to Vaccine Rule 11(a), the parties may expedite entry of judgment by each filing (either jointly or separately)
a notice renouncing their right to seek review.
2

Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 3 of 7

Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 4 of 7

Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 5 of 7

Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 6 of 7

Case 1:16-vv-00169-UNJ Document 22 Filed 01/31/17 Page 7 of 7